TGTX

Umbralisib Monotherapy (UNITY-NHL)

R/R MZL & FL

Stage (next event)

Expected Date

Data Presentation

Q4 2020

Catalyst Info & Data Links

TITLE: Umbralisib Monotherapy in Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)


WHAT IS THE CATALYST EVENT?

  • 1. Year-end-2020: Full Data Presentation

  • 2. PDUFA for MZL

  • 3. PDUFA for FL

  • *not currently planning to hold an advisory committee meeting to discuss this application


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 1. December 2020

  • 2. February 15, 2021

  • 3. June 15, 2021


PRIOR DATA


PRESS RELEASE

POSTERS


PRESENTATIONS

  • 2019: Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study (International Congress on Malignant Lymphoma)

  • 2019: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/ refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 study (American Society of Clinical Oncology Annual Meeting) 

  • 2020: J.P. Morgan Healthcare Conference (slides 5-11)

PUBLICATIONS

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. The phosphoinositide-3-kinases (“PI3Ks”) are a family of enzymes involved in various cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity. There are four isoforms of PI3K (alpha, beta, delta, and gamma), of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas.


  • Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently approved PI3K delta inhibitors have been associated with autoimmune mediated toxicities such as liver toxicity, lung toxicity and colitis. We believe the specificity differences of umbralisib, as compared to the approved PI3K inhibitors, its unique inhibition of CK1 epsilon, as well as its distinct and patented chemical structure may differentiate umbralisib within the PI3K inhibitor class.

Source

COMPETITORS

MARKET

  • ~22,500 new cases per year in MZL and FL

  • ~6,000-10,0002 relapsed indolent patients needing treatment each year

  • source - 2020 J.P. Morgan Healthcare Conference (slide 10)


Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ASCO 2018 Amp Noteworthy Abstracts

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon